Post-COVID-19 Tissue Remodeling and Multiorgan Damage: Pathogenetic Mechanisms, Structural Alterations, and Long-Term Clinical Consequences of SARS-CoV-2 Infection

Authors

  • Dadamukhamedova Khalida Erkinovna Tashkent State Medical University
  • Khurramov Arslonbek Fazliddin ugli Tashkent State Medical University
  • Sayfiddinov Doniyor Tursunali ugli Tashkent State Medical University
  • Kupaysinov Umidjon Asad ugli Tashkent State Medical University

Keywords:

SARS-CoV-2, COVID-19, post-COVID-19 condition, long COVID, tissue damage, inflammation, fibrosis, endothelial dysfunction, microcirculation, pulmonary fibrosis, skeletal muscle, multiorgan injury

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily recognized as an acute respiratory infection; however, accumulated evidence demonstrates that its biological effects extend far beyond the respiratory tract. Materials and Methods. A narrative analytical review of published scientific literature on post-COVID-19 tissue injury was performed. Particular attention was given to studies addressing persistent inflammation, viral persistence, endothelial and microvascular injury, fibrotic remodeling, skeletal muscle pathology, and multiorgan involvement. Publications from peer-reviewed journals and authoritative international sources were evaluated with emphasis on pulmonary, cardiovascular, renal, muscular, neurological, and vascular changes. Results. Post-COVID-19 tissue pathology appears to result from several interacting mechanisms, including residual injury from acute infection, dysregulated immune activation, endothelial damage, microcirculatory impairment, persistent or residual viral material in selected tissues, oxidative stress, mitochondrial dysfunction, and profibrotic signaling. Pulmonary interstitial abnormalities and fibrosis are particularly evident after severe disease, whereas endothelial and microvascular abnormalities may contribute to multisystem symptoms. Skeletal muscle abnormalities, inflammatory changes, impaired energy metabolism, and reduced exercise tolerance have also been reported. Persistent structural damage does not occur uniformly in all patients, and the extent of tissue injury depends on acute disease severity, pre-existing disorders, age, immunological response, and other host-related factors. Conclusion. SARS-CoV-2 infection may produce prolonged structural and functional changes in multiple tissues. Post-COVID-19 complications should therefore be considered a multisystem pathophysiological process rather than exclusively a respiratory sequela. Evaluation of tissue remodeling, endothelial dysfunction, inflammatory activation, and fibrosis may improve understanding of persistent symptoms and support individualized follow-up strategies.

References

[1] World Health Organization, A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. Geneva, Switzerland: WHO, 2021.

[2] World Health Organization, “Post COVID-19 condition.” [Online]. Available: https://www.who.int/

[3] H. E. Davis, G. McCorkell, J. M. Vogel, and E. J. Topol, “Long COVID: Major findings, mechanisms and recommendations,” Nature Reviews Microbiology, vol. 21, pp. 133–146, 2023.

[4] D. Chertow, S. Stein, S. Ramelli et al., “SARS-CoV-2 infection and persistence in the human body and brain at autopsy,” Nature, 2022.

[5] J. J. Solomon, B. Heyman, J. P. Ko, R. Condos, and D. A. Lynch, “Post-COVID interstitial lung abnormalities: Incidence and management,” 2023.

[6] B. Appelman, B. T. Charlton, R. P. Goulding et al., “Muscle abnormalities worsen after post-exertional malaise in long COVID,” Nature Communications, vol. 15, Art. no. 17, 2024.

[7] Y. Shu, L. He, and C. Liu, “Impact of anti-fibrotic medications on post-COVID-19 pulmonary fibrosis: A systematic review and meta-analysis,” International Journal of Infectious Diseases, vol. 147, Art. no. 107193, 2024.

[8] World Health Organization, “Post COVID-19 condition (Long COVID): Key facts.” [Online]. Available: https://www.who.int/

[9] T. Greenhalgh, M. Sivan, A. Perlowski, and J. Ž. Nikolich, “Long COVID: A clinical update,” The Lancet, vol. 404, no. 10453, pp. 707–724, 2024, doi: 10.1016/S0140-6736(24)01136-X.

[10] M. J. Peluso and S. G. Deeks, “Mechanisms of long COVID and the path toward therapeutics,” Cell, vol. 187, no. 20, pp. 5500–5529, 2024, doi: 10.1016/j.cell.2024.07.054.

[11] World Health Organization, Clinical Management of COVID-19: Living Guideline, 18 August 2023. Geneva, Switzerland: WHO, 2023. [Online]. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-2023.2

[12] World Health Organization, Rehabilitation Needs of People Recovering from COVID-19: Scientific Brief, 29 November 2021. Geneva, Switzerland: WHO, 2021. [Online]. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Rehabilitation-2021.1

[13] National Institute for Health and Care Excellence, COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19, NICE Guideline NG188. London, U.K.: NICE, 2020, updated Jan. 25, 2024. [Online]. Available: https://www.nice.org.uk/guidance/ng188

[14] Centers for Disease Control and Prevention, “Long COVID clinical guidance,” updated Mar. 9, 2026. [Online]. Available: https://www.cdc.gov/long-covid/hcp/clinical-guidance/index.html

[15] World Health Organization, “Coronavirus disease (COVID-19): Post COVID-19 condition,” Mar. 28, 2023. [Online]. Available: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-%28covid-19%29-post-covid-19-condition

Downloads

Published

2026-10-11

How to Cite

Erkinovna, D. K., ugli, K. A. F., ugli, S. D. T., & ugli, K. U. A. (2026). Post-COVID-19 Tissue Remodeling and Multiorgan Damage: Pathogenetic Mechanisms, Structural Alterations, and Long-Term Clinical Consequences of SARS-CoV-2 Infection. International Journal of Integrative and Modern Medicine, 4(10), 22–29. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/3014